| Title |
Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta‐analysis
|
|---|---|
| Published in |
Cochrane database of systematic reviews, November 2019
|
| DOI | 10.1002/14651858.cd013487 |
| Pubmed ID | |
| Authors |
Vanessa Piechotta, Tina Jakob, Peter Langer, Ina Monsef, Christof Scheid, Lise J Estcourt, Sunday Ocheni, Sebastian Theurich, Kathrin Kuhr, Benjamin Scheckel, Anne Adams, Nicole Skoetz |
X Demographics
The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 2 | 11% |
| Qatar | 1 | 6% |
| Ireland | 1 | 6% |
| Curaçao | 1 | 6% |
| United Kingdom | 1 | 6% |
| United States | 1 | 6% |
| Unknown | 11 | 61% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 15 | 83% |
| Practitioners (doctors, other healthcare professionals) | 3 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 177 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 177 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 21 | 12% |
| Researcher | 20 | 11% |
| Other | 19 | 11% |
| Student > Master | 14 | 8% |
| Student > Ph. D. Student | 12 | 7% |
| Other | 23 | 13% |
| Unknown | 68 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 21% |
| Nursing and Health Professions | 13 | 7% |
| Biochemistry, Genetics and Molecular Biology | 10 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 5% |
| Psychology | 7 | 4% |
| Other | 27 | 15% |
| Unknown | 74 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 34. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 January 2024.
All research outputs
#1,179,068
of 25,595,500 outputs
Outputs from Cochrane database of systematic reviews
#2,454
of 13,156 outputs
Outputs of similar age
#28,090
of 478,133 outputs
Outputs of similar age from Cochrane database of systematic reviews
#38
of 187 outputs
Altmetric has tracked 25,595,500 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,156 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.8. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 478,133 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 187 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.